INSMED Inc (NASDAQ: INSM) CEO executes 10b5-1 option exercise and sale of 10,699 shares
Rhea-AI Filing Summary
INSMED Inc Chair and CEO William Lewis reported a series of equity transactions in company common stock. He exercised stock options covering 10,699 shares at exercise prices of $17.16 and $30.46 per share and sold 10,699 shares of common stock in multiple open-market transactions at prices ranging from approximately $116.01 to $118.80 per share. The sales were effected pursuant to a pre-established Rule 10b5-1 trading plan. Lewis also reports 233,924 shares of common stock held indirectly by a trust.
Positive
- None.
Negative
- None.
Insights
CEO executed a planned option exercise-and-sell with no clear thesis change signal.
William Lewis, Chair and CEO of INSMED Inc, exercised stock options for 10,699 common shares at exercise prices of $17.16 and $30.46 per share. On the same July 9, 2026, he sold an equal number of shares in open-market transactions at prices between roughly $116.01 and $118.80 per share.
The filing specifies that these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on September 4, 2025, which makes the timing more mechanical than discretionary. A separate holding entry shows 233,924 shares held indirectly by trust, and a footnote notes 141 shares acquired through the 2018 Employee Stock Purchase Plan, underscoring that Lewis continues to have substantial equity exposure.
The pattern is a typical compensation-driven exercise-and-sell: options are converted into shares, then sold to realize value, while other direct and indirect holdings remain. Investors may focus on the pre-planned nature of the trades and the continued trust holdings when assessing any sentiment signal from these transactions.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 6,259 | $0.00 | -- |
| Exercise | Stock Option (right to buy) | 4,440 | $0.00 | -- |
| Exercise | Common Stock | 6,259 | $30.46 | $191K |
| Exercise | Common Stock | 4,440 | $17.16 | $76K |
| Sale | Common Stock | 5,005 | $116.55 | $583K |
| Sale | Common Stock | 2,335 | $117.62 | $275K |
| Sale | Common Stock | 3,359 | $118.52 | $398K |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Includes 141 shares acquired through the Company's 2018 Employee Stock Purchase Plan. This is the weighted average sales price representing 5,005 shares sold at prices ranging from $116.01 to $117.00 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. This is the weighted average sales price representing 2,335 shares sold at prices ranging from $117.05 to $117.96 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. This is the weighted average sales price representing 3,359 shares sold at prices ranging from $118.06 to $118.80 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.